Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.Blood · 2026Article
- Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights.British journal of haematology · 2025Review
- Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.Blood cancer journal · 2025Article
- Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsedHaematologica · 2025Article
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development.American journal of hematology · 2025Review
- Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy.Blood advances · 2025Article
- Review
- Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Bone marrow transplantation · 2025Review
- Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?Leukemia · 2025Review
- Article
- Mutation- and MRD-informed treatments for transplant-ineligible patients.Hematology. American Society of Hematology. Education Program · 2024Review
- Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse.
methodsPatients with either MRD (≥1 log
resultsForty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32%
conclusionFor AML in first remission and either MRD or oligoblastic relapse, venetoclax plus LDAC is well tolerated and highly effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.